{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:54Z","timestamp":1787032854901,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,24]]},"DOI":"10.7759\/cureus.42388","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T13:44:15Z","timestamp":1690206255000},"source":"Crossref","is-referenced-by-count":1,"title":["Toe Gangrene as the First Presenting Symptom of Essential Thrombocythemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Mahmoud M","family":"Altayyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abu-Tineh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Afana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen A","family":"Toba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3004","article-title":"MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria","volume":"9","author":"Yassin MA","year":"2020","unstructured":"Yassin MA, Taher A, Mathews V, et al.. MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med. 2020, 9:4512-26. 10.1002\/cam4.3004","journal-title":"Cancer Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221086396","article-title":"Assessing bone marrow activity with [18F]FLT PET in patients with essential thrombocythemia and prefibrotic myelofibrosis: a proof of concept","volume":"21","author":"Yassin MA","year":"2022","unstructured":"Yassin MA, Nehmeh SA, Nashwan AJ, et al.. Assessing bone marrow activity with [18F]FLT PET in patients with essential thrombocythemia and prefibrotic myelofibrosis: a proof of concept. Technol Cancer Res Treat. 2022, 21:15330338221086396. 10.1177\/15330338221086396","journal-title":"Technol Cancer Res Treat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.12.009","article-title":"Clinical exome sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: a pilot study in patients from the state of Qatar","volume":"689","author":"Al-Dewik N","year":"2019","unstructured":"Al-Dewik N, Ben-Omran T, Zayed H, Trujillano D, Kishore S, Rolfs A, Yassin MA. Clinical exome sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: a pilot study in patients from the state of Qatar. Gene. 2019, 689:34-42. 10.1016\/j.gene.2018.12.009","journal-title":"Gene"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.5244.5244","article-title":"Familial essential thrombocythemia among Qatari tribes","volume":"122","author":"Yassin MA","year":"2013","unstructured":"Yassin MA, Al-Dewik NI, ElAyoubi H, Cassinat B. Familial essential thrombocythemia among Qatari tribes. Blood. 2013, 122:5244. 10.1182\/blood.V122.21.5244.5244","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia","volume":"83","author":"Ma X","year":"2008","unstructured":"Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008, 83:359-62. 10.1002\/ajh.21129","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson P","year":"2006","unstructured":"Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006, 32:171-3. 10.1055\/s-2006-939430","journal-title":"Semin Thromb Hemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939431","article-title":"Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications","volume":"32","author":"Michiels JJ","year":"2006","unstructured":"Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006, 32:174-207. 10.1055\/s-2006-939431","journal-title":"Semin Thromb Hemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"Bose P","year":"2019","unstructured":"Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019, 10:2040620719870052. 10.1177\/2040620719870052","journal-title":"Ther Adv Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1693477","article-title":"Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms","volume":"45","author":"Arachchillage DR","year":"2019","unstructured":"Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost. 2019, 45:604-11. 10.1055\/s-0039-1693477","journal-title":"Semin Thromb Hemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113248","article-title":"Impact of myeloproliferative neoplasms (MPNs) on health-related quality of life (HRQOL) and medical resource utilization: results from the MERGE registry","volume":"132","author":"Taher A","year":"2018","unstructured":"Taher A, Yassin MA, Xiao Z, et al.. Impact of myeloproliferative neoplasms (MPNs) on health-related quality of life (HRQOL) and medical resource utilization: results from the MERGE registry. Blood. 2018, 132:4311. 10.1182\/blood-2018-99-113248","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4054.4054","article-title":"Efficacy and safety of pegelated interferon alpha2a once monthly compared to once weekly dose in patients with essential thrombocythemia.","volume":"122","author":"Yassin MA","year":"2013","unstructured":"Yassin MA, Al-Dewik NI, ElAyoubi H, Cassinat B. Efficacy and safety of pegelated interferon alpha2a once monthly compared to once weekly dose in patients with essential thrombocythemia..  Blood. 2013, 122:4054. 10.1182\/blood.V122.21.4054.4054","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.33756","article-title":"The risk of thrombosis in essential thrombocythemia and polycythemia vera","volume":"29","author":"Pearson TC","year":"2002","unstructured":"Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002, 29:16-21. 10.1053\/sonc.2002.33756","journal-title":"Semin Oncol"},{"key":"ref13","article-title":"Prognosis and treatment of essential thrombocythemia","author":"Tefferi A","year":"2023","unstructured":"Tefferi A. Prognosis and treatment of essential thrombocythemia. UpToDate. Larson RA, Rosmarin AG (ed): UpToDate, Waltham, MA; 2023."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900801)66:3<549::aid-cncr2820660324>3.0.co;2-6","article-title":"Clinical course of essential thrombocythemia in 147 cases","volume":"66","author":"Fenaux P","year":"1990","unstructured":"Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990, 66:549-56. 10.1002\/1097-0142(19900801)66:3&lt;549::aid-cncr2820660324&gt;3.0.co;2-6","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger H","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, et al.. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013, 121:1720-8. 10.1182\/blood-2012-07-443770","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison CN","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, et al.. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005, 353:33-45. 10.1056\/NEJMoa043800","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996123","article-title":"Interferon-alpha therapy in polycythemia vera and essential thrombocythemia","volume":"23","author":"Elliott MA","year":"1997","unstructured":"Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 1997, 23:463-72. 10.1055\/s-2007-996123","journal-title":"Semin Thromb Hemost"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian JJ","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008, 22:1990-8. 10.1038\/leu.2008.280","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian JJ","year":"2011","unstructured":"Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011, 117:4706-15. 10.1182\/blood-2010-08-258772","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger E","year":"2015","unstructured":"Verger E, Cassinat B, Chauveau A, et al.. Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015, 126:2585-91. 10.1182\/blood-2015-07-659060","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131155-toe-gangrene-as-the-first-presenting-symptom-of-essential-thrombocythemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:02:09Z","timestamp":1707490929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131155-toe-gangrene-as-the-first-presenting-symptom-of-essential-thrombocythemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.42388","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}